Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | LTA · HBM Demand · Valuation Re-rating / 2026-05-27 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | BBU Momentum · Hungarian Utilization Rebound · 2026 Operating Profit Turnaround / 2026-03-18 Research
  • [Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [Research] LIG D&A (079550) – Eugene Investment & Securities | Non-Cheongung Potential · High-margin Legacy Defense · Earnings Surprise / 2026-05-08 Research
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI Server Demand · Supply Deficit · FCBGA Technical Bottleneck / 2026-07-20 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | AI Infrastructure · LTA · HBM Demand / 2026-06-09 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | 4Q Earnings Recovery · New Plant Ramp-up · Peptide Expansion / 2026-07-24 Research

[Research] Samsung SDI (006400) – DS Investment & Securities | 4Q Turnaround Visibility · Non-PFE LFP ESS · European Volume Models / 2026-04-29

Posted on April 29, 2026August 22, 2026 By ksb220805@gmail.com

Brokerage : DS Investment & Securities

Analyst : Tae-yong Choi

Investment Rating : BUY (Maintained)

Target Price : KRW 840,000 (Raised)

Core Momentum : Increasing visibility toward a 4Q26 operating profit turnaround, supported by expansion into European volume EV models and the ramp-up of the North American SPE LFP line leveraging Non-PFE supply chain strengths for ESS orders.

📊 1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: BUY (Maintained), Target Price KRW 840,000 (Raised by shifting the valuation base year to 2027 and removing the 50% private asset discount in light of the planned Samsung Display stake monetization)
  • Market Data (As of 2026-04-28): Current Price KRW 680,000 (Upside Potential 23.5%), Market Cap KRW 54.80 Trillion, Shares Outstanding (Common) 80.59 Million, Foreign Ownership 23.35%
  • Key Financial Forecasts (2025F → 2026F → 2027F):
    • Revenue: KRW 13.27 Trillion → KRW 15.31 Trillion → KRW 19.13 Trillion
    • Operating Profit: KRW -1.998 Trillion → KRW -236.0 Billion (Loss Narrowed) → KRW 1.21 Trillion (Turnaround)
    • Pre-tax Profit: KRW -1.36 Trillion → KRW 115.0 Billion (Turnaround) → KRW 1.46 Trillion
    • Net Profit (Controlling): KRW -649.0 Billion → KRW 30.0 Billion (Turnaround) → KRW 951.0 Billion
    • EPS: KRW -8,426 → KRW 367 (Turnaround) → KRW 12,290
    • Operating Margin (OPM): -15.1% → -1.5% → 6.3%
    • ROE: -3.2% → 0.1% → 4.7%
    • PER / PBR: -80.7x / 2.6x → 1,854.4x / 2.8x → 55.3x / 2.7x
    • EV/EBITDA: 610.5x → 28.2x → 15.3x

🚀 2. [Market Opportunities & Business Outlook]

  • 1Q26P Earnings Review: Revenue reached KRW 3.6 Trillion (QoQ -7.3%, YoY +12.6%) and Operating Loss came in at KRW -155.6 Billion (Loss continued QoQ/YoY), beating consensus. Margin improvement was driven by favorable mix shifts in ESS and small batteries. ESS delivered mid-single-digit margins despite seasonal headwinds due to higher UPS mix (rising from 25% in 4Q25 to 30% in 1Q26). Small batteries improved on rising BBU and tabless power tool shipments. Prismatic EV losses narrowed backed by European shipments from the US SPE plant (recognizing ~50% of the KRW 80.5 Billion AMPC) and additional compensation.
  • 2Q26F Earnings Outlook: Projected Revenue of KRW 3.6 Trillion (QoQ +0.9%, YoY +13.4%) and Operating Loss of KRW -70.2 Billion. Loss reduction continues driven by the mass production of new European volume EV models in Hungary and SPE European shipments. ESS profitability is expected to expand to high-single digits on deferred shipments and higher UPS contribution.
  • 4Q26 Turnaround & Medium-Term Catalysts:
    • ESS Acceleration: Full-year ESS revenue is projected to grow over +50% YoY, propelled by the startup of the US SPE LFP line in 4Q26 and robust UPS demand. Non-PFE supply chain advantages are expected to serve as core competitive drivers for winning hyperscaler orders and triggering an ESS valuation re-rating.
    • EV Segment Expansion: European volume model entry and the recovery of Hungarian plant utilization (1Q26 50% → 2H26 70%) will help overcome previous exposure limits concentrated in premium OEM segments.

📝 Editor’s Comment (Perspective)

The analyst views Samsung SDI as a turnaround battery manufacturer overcoming historical customer concentration in premium segments by entering mass-market European volume models and deploying Non-PFE-compliant LFP ESS solutions to win global tech accounts. This perspective places primary importance on operational recovery milestones—such as rising Hungarian plant utilization and the 4Q26 launch of North American LFP capacity securing a return to operating profitability—alongside balance sheet valuation normalization following the planned monetization of its Samsung Display stake.

To evaluate the ongoing validity of this investment thesis, key monitoring factors include the commercial launch and yield stabilization of the US SPE LFP line in 4Q26, the recovery of Hungarian plant utilization toward the 70% level in 2H26, and concrete new ESS order wins from global hyperscalers leveraging Non-PFE supply chain compliance. These operational developments can be tracked through upcoming quarterly financial announcements, company IR presentations, and periodic statutory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, EV & Battery

Post navigation

Previous Post: [Research] Samsung SDI (006400) – Hanwha Investment & Securities | Sequential Segment Recovery · Order Pipeline Visibility · Form Factor Diversification / 2026-04-29
Next Post: [Research] Samsung SDI (006400) – Hana Securities | Plant Utilization Recovery · North America ESS Demand · Valuation Re-rating / 2026-04-29

Related Posts

  • [Research] LIG D&A (079550) – Kiwoom Securities | Defense Export Expansion · GR Turnaround · 2026E Upward / 2026-02-19 Research
  • [Research] Samsung SDI (006400) – Kyobo Securities | AI Data Center BBU · Direct CSP Channels · 1Q Earnings Beat / 2026-04-29 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Keytruda SC Growth Accelerates · Favorable Contract Terms · Early June PGR Catalysts / 2026-05-11 Research
  • [Research] LigaChem Biosciences (141080) – iM Securities | Platform Valuation · Pipeline Milestones · Deal Expansion / 2025-08-12 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research
  • [Research] SK hynix (000660 / SKHY) – Hyundai Motor | Supply Shortage · Memory ASP · Profitability / 2026-01-30 Research
  • [Research] LIG D&A (079550) – DS Investment & Securities | Order Expansion · Iraq Cheongung-II Mass Production · Long-term Earnings Growth / 2026-08-07 Research
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Server Memory Demand · HBM3E Pricing · Margin Expansion / 2026-01-30 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | Plant 5 PPQ Revenue · US Site Consolidation · Guidance Revision Potential / 2026-04-23 Research
  • [Research] Samsung Biologics (207940) – Kyobo Securities | H2 Revenue Recognition · Modality Diversification · Earnings Growth / 2026-07-24 Research
  • [Research] Samsung Biologics (207940) – iM Securities | Annual Operating Profit Surpasses KRW 2T · Pure-CDMO Transition · Three-Pillar Growth Strategy / 2026-01-22 Research
  • [Research] Samsung SDI (006400) – Hana Securities | North America JV Resolution · ESS Line Conversion · Earnings Estimate Upgrades / 2026-08-12 Research
  • [Research] LIG D&A (079550) – Eugene Investment & Securities | Non-Cheongung Potential · High-margin Legacy Defense · Earnings Surprise / 2026-05-08 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Defense Export Expansion · GR Turnaround · 2026E Upward / 2026-02-19 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme